

Cite this: *Anal. Methods*, 2019, 11, 3090

^{19}F and ^1H quantitative-NMR spectroscopic analysis of fluorinated third-generation synthetic cannabinoids†

Husain A. Naqi, Timothy J. Woodman,  Stephen M. Husbands and Ian S. Blagbrough *

Quantitative nuclear magnetic resonance (q-NMR) spectroscopy is a robust and reliable analytical method that possesses many advantages over conventional chromatographic techniques used in drug analysis. In this paper, the application of ^{19}F and ^1H NMR spectroscopy to quantify the amounts of synthetic cannabinoids (SCs), AM-694 and 5F-ADB, in herbal incense packages is discussed. These SC samples, seized in the South West of England in the summers of 2016 and 2017, are part of a growing illicit drug problem in the UK. For accurate quantitative analysis using ^{19}F observe, the data acquisition and the NMR processing parameters, such as spectral width, the centre point of the spectrum, nuclear Overhauser effect (NOE) enhancement and relaxation delay, are discussed together with cross-method validation. The reproducibility, simplicity, high speed, and non-destructive nature provide reliable quantitative analysis and, by using ^{19}F NMR, there is essentially no background interference. This quantitation is without resorting to the use of (often unavailable) standards as reference materials or to lengthy sample preparation, which are the norm in many analytical chromatographic techniques. The NMR methods allowed a direct comparison between ^1H and ^{19}F NMR, revealing the robustness and the effectiveness of ^{19}F NMR for application as a rapid (~ 8 min), quantitative analytical method for fluorinated SCs which are now being seized with an increasing frequency and are highly toxic.

Received 17th April 2019

Accepted 1st May 2019

DOI: 10.1039/c9ay00814d

rsc.li/methods

Introduction

Synthetic cannabinoids (SCs), also known by their street name “spice”, are potent agonists binding to the cannabinoid receptors CB_1 and CB_2 distributed throughout the central nervous system (CNS) and immune system, respectively, producing psychoactive effects similar to, and in most cases more potent than, the mainstream drugs they are mimicking, e.g. Δ^9 -tetrahydrocannabinol (THC).¹ Unlike Δ^9 -THC, a partial agonist with low affinity for the CB_1 receptor, SCs are full receptor agonists with high affinity binding to CB_1 and moreover they also possess CB_2 receptor affinity.² These pharmacological characteristics result in drug users/abusers having severe physical and psychiatric episodes, not present with traditional cannabis smoking. These effects are described as the “cannabinoid tetrad”, which are hypothermia, analgesia, catalepsy, and

locomotor activities, leading to symptoms ranging from excited delirium to kidney damage.²

In 2008, the first generation of synthetic cannabinoids hit the streets,³ such as the Pfizer compound CP 47,497 and the John W. Huffman designed JWH-018 (Fig. 1). Typically these ligands were designed and developed as medicinal chemistry compounds, intended to exploit the pathological implications of the CB receptors in many diseases, but they were side-tracked to the illicit clandestine designer-drug market.^{4,5} The following generations of SC were based initially on JWH-018, but they have evolved with variations of fluoroalkyls (AM-694), indazoles (5F-ADB), quinoline (5F-PB22) and amides (PX-1) integrated into their structures, replacing the naphthoylindole of JWH-018.^{6,7} The continuous and rapid change in substituents on the available SCs makes them a moving target posing many analytical challenges. The Korean National Forensic Services reported that from 2008 to 2010 most of the SCs seized were first generation non-fluorinated compounds,⁸ e.g. JWH-018, CP 47,497, and UR-144 (Fig. 1). In 2012, fluorinated analogues started emerging such as XLR-11, a fluoropentyl analogue of UR-144, and by 2013 approximately 90% of the SCs seized were fluorinated.⁸ It is believed that the growing trend in the bio-isosteric fluorine introduction into SCs was inspired by a Makriyannis patent,⁹ where he demonstrated a much higher potency of AM-2201 than that of non-fluorinated analogues, e.g.

Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK.
E-mail: prs1sb@bath.ac.uk; Tel: +44 (0)1225 386795

† Electronic supplementary information (ESI) available: Fig. S1 shows the ^{19}F -NMR (^1H coupled) stacked spectra of 5F-ADB with its ^{19}F signal at -220.2 ppm and the IS 2-chloro-4-fluorotoluene (-117.8 ppm) with different O1P set at (A) -165 ppm, (B) -220 ppm, and (C) -117 ppm, with (inset) expansion of the of 5F-ADB ^{19}F signal. Fig. S2 shows 5F-ADB quantified in a sample using ^1H , ^{19}F proton coupled, and ^{19}F inverse-gated decoupled spectroscopy. See DOI: 10.1039/c9ay00814d



JWH-018 (Fig. 1). Initially, AM-2201 was identified in herbal blends, and this has escalated into many SCs with no precedent in the scientific literature, *e.g.* 5F-ADB-PINACA, 5F-AB-PICA, and 5F-PB-22.⁵ The third-generation SCs include fluorinated AM-694 and 5F-ADB (Fig. 1). Also, besides the enhanced potency of fluorinated analogues, the addition of a fluorine substituent was possibly intended to circumvent legal restrictions imposed on specified SCs.^{5,10}

¹H-NMR is inherently quantitative, as the integrated functional group signals are directly proportional to the number of spins generated by the signals in question. Nevertheless, NMR is only quantitative if the appropriate acquisition and processing parameters are determined by experiment and then implemented. Early applications of quantitative NMR (q-NMR), using low-field instruments, required considerably large amounts of sample and Internal Standard (IS).¹¹ The development of high-field NMR spectrometers facilitated improved sensitivity meaning that impurities could be quantified at less than 0.1% of the total sample, demonstrating that NMR is comparable with chromatographic methods for quantitative analysis.^{12–15} NMR has more advantages than other analytical approaches such as those that are chromatography based. NMR does not require the use of a high purity reference standard for the construction of the required calibration curve. Such a standard is expensive and

often unavailable, especially for newer, more recently identified SCs.¹⁴ NMR also has the advantage of less sample preparation being required. No serial dilution is required to run the sample and no mobile phase has to be prepared. Also, as there is no interaction with a column, no blank samples are required to be chromatographed in order to avoid carry-over that could affect the analysis. NMR is not subject to problems from small compounds and impurities with no chromophore or a different UV response which pose challenges to chromatographic and UV methods.^{14,15}

Quantitative analysis of SCs in herbal blends has been reported using some analytical techniques, mostly chromatography and MS-based ones.¹⁶ GC/MS showed qualitative and quantitative variations among SCs in herbal-blend brands in 2014.¹⁷ ¹H q-NMR reports on SC quantitation are scarce, but there is a report on purchased herbal blends containing SCs using maleic acid (MA) as an internal standard.¹⁸ A study on the extraction efficiency of common solvents, *e.g.* acetone, acetonitrile, chloroform, and methanol, using ¹H q-NMR with 1,3,5-trimethoxybenzene as an internal standard and GC/MS on seized herbal blends and in-house preparations found no significant difference between the solvents used for the SC extraction.¹⁹




Fig. 1 1st, 2nd, and 3rd generation SCs.



The ^{19}F nucleus is attractive for q-NMR spectroscopy, mainly due to the sensitivity of the nucleus (its relative sensitivity is 83.4% of ^1H) and its natural abundance of 100%.²⁰ Additionally, the wide range of chemical shift (500 ppm) reduces the chance of overlapping signals, and the absence of fluorinated impurities inherently means that there is less background noise.²¹ ^{19}F q-NMR has been applied to analyse fluorinated Active Pharmaceutical Ingredients (API).²² Nevertheless, for quantitative results more NMR parameters have to be addressed than for ^1H q-NMR,²¹ e.g. equal excitation for the signals across the entire spectral width must be achieved, otherwise the integration values will suffer which in turn affects the analytical results. This is achieved by setting the centre point of the spectral window midway between the signal of the internal standard and the compound, using a 90° pulse angle followed by a sufficient relaxation delay of $5 \times T_1$ to recover the magnetization to 99.3% of its size. The use of a suitable relaxation delay is common with ^1H q-NMR. If the ^{19}F spectrum is acquired with broadband ^1H decoupling, then NOE enhancement of the signals may arise. In order to avoid this, an inverse-gated decoupling sequence is used.²¹

A validated ^{19}F q-NMR spectroscopic method is reported for the first time to quantify fluorinated SCs, e.g. AM-694 and 5F-ADB (Fig. 1), in herbal blends recently seized in the South West of England. The technique was compared to both ^1H q-NMR and UHPLC for accurate quantification and was shown to be in good agreement. Moreover, quantitative differences between seized sample batches are discussed. This investigation of the acquisition parameters associated with ^{19}F q-NMR will help drug analysts to run a fast and robust quantitative analysis for fluorinated (illicit) drugs with minimal background interference and signal overlap. It is important because such highly toxic SCs are currently being found with increasing frequency and outbreaks of zombification caused by AMB-FUBINACA have been reported in *NEJM*,²³ and in various UK cities in the popular press.

Experimental section

Chemicals and sample preparation

Extraction solvents (all 99.9% anhydrous) chloroform, methanol, and acetonitrile were purchased from Fisher Scientific (UK) and ACROS Organics (UK). Deuterated solvents (CDCl_3 , CD_3OD , and CD_3CN) were purchased from Cambridge Isotope Laboratories (Goss Scientific, UK). NMR internal standards (IS) 2-chloro-4-fluorotoluene, dimethyl sulfone (DMS), and maleic acid (MA) are TraceCERT certified reference materials purchased from Sigma-Aldrich (UK). [1-(5-Fluoropentyl)-1*H*-indol-3-yl](2-iodophenyl)-methanone (AM-694) 10.0 mg, *N*-(1-adamantyl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide (5F-AKB-48) 1.0 mg mL^{-1} in a 1.0 mL vial, and (1-pentyl-1*H*-indol-3-yl)-1-naphthalenyl-methanone (JWH-018) 100 $\mu\text{g mL}^{-1}$ in a 1.0 mL vial were purchased from LGC (Teddington, UK). *N*-Methyltrifluoroacetamide (*N*-methyl-TFA) >98.0% was purchased from Tokyo Chemical Industry (TCI, Tokyo, Japan). SC samples were provided by the Drug Expert Action Team (DEAT), Avon and Somerset Constabulary, from recent (2016–2017) seizures.

The samples were in the form of herbal blends (1.0–3.0 g) as commercially packaged brands (Exodus, Loco Elite). *Turnera diffusa* (damiana) dried herb (illicit-drug free) was purchased from Spiceworks (Hereford, UK).

All standards and samples were weighed using a SE2F Sartorius analytical balance, between 1.0 and 2.0 mg mL^{-1} IS was used. Preliminary analysis of non-homogenized herbal-blend samples yielded large variations in the amounts of the SCs sprayed on the carrier plant materials between samples tested by NMR. Therefore, two approaches were employed for the homogenization of the herbal-blend samples. Either they were ground to a fine powder with 100 grit sandpaper²⁴ or they were frozen in liquid nitrogen, followed by grinding to a fine powder using a mortar and pestle. For sample preparation for UHPLC and NMR analyses, homogenized plant materials (100 mg) were extracted with methanol (2×4.0 mL) with sonication (30 min) at 20°C , centrifuged, and then the supernatant extract was decanted and the pellet (plant material) discarded. The extract was then evaporated to dryness under reduced pressure and reconstituted in deuterated solvent (1.0 mL) containing the IS (DMS, MA or 2-chloro-4-fluorotoluene) for NMR spectroscopic analysis. For UHPLC analysis, samples were diluted 100-fold in UHPLC solvent to bring them within the calibration range. AM-694 was quantified using a 7-point calibration curve between 1.25 and 80 $\mu\text{g mL}^{-1}$ with JWH-018 as the IS. 5F-ADB was quantified using a 6-point calibration curve between 1.25 and 40 $\mu\text{g mL}^{-1}$ with 5F-AKB48 as the IS (10.0 $\mu\text{g mL}^{-1}$). The response was calculated as the ratio of the area under the curve of the compounds to that of the respective IS. Data analysis was conducted using the Microsoft Excel data analysis tool pack.

Instrumentation

NMR spectroscopy. NMR spectra were recorded on a Bruker AVANCE III 500 MHz spectrometer. ^1H , ^{13}C , and ^{19}F frequencies are 500.13, 125.76, and 470.59 MHz, respectively. The probe was a variable temperature BBFO+ with three channels, and the temperature was 25°C . Chemical shifts were referenced to 0.0 ppm for TMS or residual (protio) solvent peaks and are reported in ppm. Coupling constants (J , line-separations, absolute values) are rounded to the nearest 0.5 Hz. An inversion recovery pulse sequence was performed to measure the longitudinal relaxation time T_1 for the 2-chloro-4-fluoro-toluene IS and 5F-ADB. The T_1 relaxation delay for the IS signal for ^1H quantification for H5 (^1H δ = 6.98 ppm, 1H, td 8.5, 2.5 Hz) was 5.7 s, and T_1 for the indazole 5F-ADB ranged from 2.9–3.5 s. For quantitative ^1H NMR, the pulse sequence was composed of 64k data points, an acquisition time of 3.18 s, 16 scans, 50 s delay, and 90° pulse angle; integration was performed manually. All NMR spectra were acquired using Bruker TopSpin 2.1 and processed using either Bruker TopSpin 3.5 or Mestralab Mnova 11.2. The ^{19}F q-NMR proton coupled and inverse gated pulse sequence used a sweep of 241.51 ppm, O1P –168 ppm, 6k point counts, an acquisition time of 0.7 s, 16 scans, 30 s delay, and 90° pulse angle; phase and baseline correction and integration were performed manually. Structural elucidation was achieved with



the use of 2D NMR spectroscopy. Eqn (1) was used for ^1H q-NMR quantitation:

$$m(x) = P(\text{std}) \frac{M_w(x)}{M_w(\text{std})} \frac{A(x)}{A(\text{std})} m(\text{std}) \frac{N(\text{std})}{N(x)} \frac{m(\text{herbal package})}{m(\text{sample used})} \quad (1)$$

where x is the analyte, std is the IS, m is the mass in mg, P is the purity, M_w is the molecular weight in g mol^{-1} , A is the integral value of the resonance being investigated, N is the number of protons represented by the signal, $m(\text{herbal package})$ is the mass of the herbal package in mg and $m(\text{sample used})$ is the mass of the extracted sample in mg.

UHPLC-ESI-MS/MS. The UHPLC-ESI-QTOF MS analysis was conducted using a MaXis HD quadrupole electrospray ionization time-of-flight (ESI-QTOF) mass spectrometer (MS) (Bruker Daltonik GmbH, Bremen, Germany), operated in ESI positive-mode. The QTOF was coupled to an Ultimate 3000 UHPLC (Thermo Fisher Scientific, Sunnyvale, CA, USA). The capillary voltage was set to 4500 V, nebulizing gas at 4 bar, and drying gas at 12 L min^{-1} at 220°C . The TOF scan range was from 75 to 1000 mass-to-charge ratio (m/z). For LC-MS/MS capabilities, the in-source CID was set to 0.0 eV, with the collision energy for TOF MS acquisition at 3.0 eV. The collision energy was set to a sliding scale from 100 m/z at 14.0 eV, 500 m/z at 20.0 eV and 1000 m/z at 30.0 eV. For the analytes, the actual collision energy was between 15.0 and 18.0 eV. UHPLC calibration curve construction and sample quantitative analysis were performed on a Dionex Ultimate 3000 UHPLC with a variable wavelength detector ($\lambda = 254, 280, \text{ and } 298 \text{ nm}$). Liquid chromatography separation was performed using an Acquity UPLC BEH C18, 1.7 μM , $2.1 \times 50 \text{ mm}$ RP-column (Waters, Milford, MA, USA) with a flow rate of 0.4 mL min^{-1} , and an injection volume of 10 μL at a column temperature of 40.0°C .

Mobile phase A consisted of MS grade water with 0.1% tri-fluoroacetic acid (v/v), and mobile phase B consisted of acetonitrile with 0.1% trifluoroacetic acid (v/v). For AM-694 and 5F-ADB calibration curves and quantitation the following solvent gradient 1 was used: the gradient started from 1% B for 2.0 min followed by a linear increase to 100% B at 5.0 min, held for 3 min, followed by a return to 1% B at 8.1 min, where it was held for equilibration for 3.9 min, with a total run time of 12.0 min. For 5F-ADB purity determination, the flow rate was 0.4 mL min^{-1} , and the column temperature was 25.0°C . Gradient 2 started with 1% B until 2.0 min followed by a linear increase to 100% B at 20.0 min, held for 4.0 min, followed by a return to 10% B at 24.1 min where it was held for 10.9 min with a total run time of 35.0 min. Data analysis used the Bruker data and quant analysis 4.3 package.

Results and discussion

The 5F-ADB reference material was extracted from a seized sample (1.3 g) with CHCl_3 ($2 \times 25.0 \text{ mL}$) with sonication for 30 min each time. The combined extracts were passed through a $0.25 \mu\text{m}$ syringe filter. The filtrate was evaporated to dryness under reduced pressure yielding $\sim 90 \text{ mg}$ of residue which was purified by flash-column normal phase silica chromatography, followed by semi-preparative RP HPLC, resulting in pure 5F-

ADB (38.0 mg). Purity and confirmation of the structure were obtained by NMR, UHPLC, and HRMS (Fig. 2).

^1H NMR (500 MHz in CD_3OD): δ 8.21 (4') (1H, dd $J = 8.0, 2.0 \text{ Hz}$), 7.83 (NH) (1H, br d $J = 9.5 \text{ Hz}$), 7.64 (7') (1H, dd $J = 8.5, 1.5 \text{ Hz}$), 7.46 (6') (1H, td $J = 8.5, 1.5 \text{ Hz}$), 7.29 (5') (1H, td $J = 8.5, 2.0 \text{ Hz}$), 4.62 (2'') (1H, d $J = 9.5 \text{ Hz}$), 4.52 (1''') (2H, t $J = 7.5 \text{ Hz}$), 4.40 (5''') (2H, dt $J = 47.5, 6.0 \text{ Hz}$), 3.78 (5'') (3H, s), 2.01 (2''') (2H, quintet $J = 7.5 \text{ Hz}$), 1.73 (4''') (2H, d quintet $J = 26.0, 6.0 \text{ Hz}$), 1.41–1.47 (3''') (2H, m), 1.10 (4'') (9H, s).

^{13}C NMR (125.8 MHz in CD_3OD): δ 173.1 (1''), 164.2 (1), 142.5 (7'a), 137.3 (3'), 126.8 (6'), 124.0 (5'), 123.9 (3'a), 123.0 (4'), 111.1 (7'), 84.7 (5'''), d $^1J_{\text{CF}} = 164.0 \text{ Hz}$, 61.3 (2''), 52.5 (5''), 50.2 (1'''), 35.8 (3''), 31.0 (4''), d $^2J_{\text{CF}} = 19.5 \text{ Hz}$, 30.4 (2''), 27.1 (4''), 23.7 (3''') d, $^3J_{\text{CF}} = 5.5 \text{ Hz}$; ^{19}F observe $\delta -220.3$ (5''') F, tt $^2J_{\text{HF}} = 47.5$, $^3J_{\text{HF}} = 26.0 \text{ Hz}$. HRMS found $[\text{M} + \text{H}]^+$ 378.2193 m/z for $\text{C}_{20}\text{H}_{29}\text{FN}_3\text{O}_3$ requires 378.2187, and found $[\text{M} + \text{Na}]^+$ 400.2010 m/z for $\text{C}_{20}\text{H}_{28}\text{FN}_3\text{O}_3\text{Na}$ requires 400.2006 (Fig. 2).

5F-ADB quantified in seized herbal blends

N -[[1-(5-Fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine methyl ester (5F-ADB) was identified in seized herbal blend samples branded as "Exodus". Identification was achieved by interpretation of 2D NMR data and the LC-MS/MS fragmentation pattern. Results are confirmed by comparison with the literature with only minor differences in the NMR, due to solvent effects.^{25,26} The ^{19}F signal for q-NMR analysis is on the N -pentyl tail with its chemical shift of $\delta = -220 \text{ ppm}$ assigned as a triplet of triplets, $^2J_{\text{HF}} 47.5 \text{ Hz}$ coupling to methylene protons on position 5''' and $^3J_{\text{HF}} 26.0 \text{ Hz}$ coupling to methylene at position 4'''.

The extraction was evaluated in chloroform, methanol, and acetonitrile. The signals used for quantification in methanol were the indazole protons 4' at 8.22 ppm, 7' at 7.64 ppm, 6' at 7.46 ppm, and 5' at 7.31 ppm. In acetonitrile, the same protons were used except 6' due to an overlapping impurity. In chloroform, H-5' was excluded due to the overlap with the residual chloroform H-solvent signal; nevertheless chloroform gave a cleaner spectrum, with fewer impurities and no sugars from the matrix component (as found when methanol was the solvent of extraction) with additional signals available for integration such as the fluoropentyl methylenes 1''' and 5'''. The DMS singlet at $\delta = 3.00 \text{ ppm}$ integrating for six protons was used as an IS in CDCl_3 .

In ^{19}F q-NMR with N -methyltrifluoroacetamide, apparently significantly lower amounts of SC, using Anova two factor analysis, were obtained than in a contemporaneous analysis by ^1H q-NMR using maleic acid (IS) in methanol and acetonitrile, DMS (IS) in chloroform, and then N -methyltrifluoroacetamide in chloroform (Table 1). The reason behind this apparently lower assay result is the resonance (chemical shift) of the N -methyltrifluoroacetamide ^{19}F signal at $\delta = -75.9$ compared to the ^{19}F signal of 5F-ADB at $\delta = -220.2 \text{ ppm}$, resulting in unequal excitation. Uniform excitation across the spectrum has to be achieved in order for all the signals to get the same magnetization in the pulse sequence, thus making the centre point of the spectral window a crucial parameter when accurate and reproducible quantitative results are to be achieved for ^{19}F q-NMR.





Fig. 2 Analytical purity of 5F-ADB as tested by (A) UHPLC with RT = 22.0 min, (B) ^1H -NMR in CD_3OD with assignments, and (C) HRMS showing $[\text{M} + \text{H}]^+$ and $[\text{M} + \text{Na}]^+$.

When *N*-methyltrifluoroacetamide was evaluated as an IS for ^1H q-NMR it was shown to be as useful an IS as MA or DMS. Although apparently attractive for ^{19}F NMR with its 3 equivalent

fluorine atoms, its wide chemical shift separation from the analyte signal made it a poor choice. Rather, 2-chloro-4-fluorotoluene was used as a ^{19}F q-NMR IS with (protio) methanol as



Table 1 Quantitative analysis of a sample of 5F-ADB by ^1H NMR in CD_3OD , CD_3CN , and CDCl_3 compared to ^{19}F q-NMR using *N*-methyltri-fluoroacetamide ($n = 4$)

Nucleus, solvent (IS)	^1H in CD_3OD (MA)	^1H in CD_3CN (MA)	^1H in CDCl_3 (DMS)	^1H in CDCl_3 (<i>N</i> -Me-TFA)	^{19}F in CDCl_3 (<i>N</i> -Me-TFA)
Amount (mg g^{-1})	11.84 ± 0.28	11.06 ± 0.16	11.03 ± 0.14	11.48 ± 0.12	8.86 ± 0.19
RSD (%)	2.34	1.45	1.30	1.01	2.18

the extraction solvent and CD_3OD as the NMR solvent, resulting in a good agreement with the data from ^1H q-NMR using maleic acid (MA) as the IS. This ^{19}F NMR IS signal has a chemical shift of $\delta = -117.8$ ppm. As 5F-ADB ^{19}F resonates at $\delta = -220.2$ ppm, the central point (Bruker's O1P) was therefore set at $\delta = -165$ ppm approximately equally between both resonances resulting in equal excitation of both fluorine signals. The ^{19}F q-NMR (proton coupled) results of 5F-ADB are in agreement with the ^1H q-NMR results using maleic acid (MA) ($10.4 \pm 0.2 \text{ mg g}^{-1}$, RSD 1.6%, $n = 5$) as the IS and $9.8 \pm 0.8 \text{ mg g}^{-1}$ (RSD 7.9%, $n = 5$) was observed with 2-chloro-4-fluorotoluene as the IS, and $9.4 \pm 0.7 \text{ mg g}^{-1}$ (RSD 7.3%, $n = 5$) with ^{19}F NMR. The effect of changing the O1P was tested using the plant material (100.0 mg) containing 5F-ADB with 2-chloro-4-fluorotoluene as the IS, and setting the O1P approximately in the middle of the two signals (-165 ppm). This resulted in quantitative results in agreement with ^1H q-NMR results. Not unexpectedly, shifting the O1P to -220 and -117 ppm resulted in significantly lower

and higher integration values, respectively, and, consequently, significantly altered quantitative results as tested by *t*-tests ($p < 0.05$) (Fig. S1†). The need to set the spectral midpoint as the excitation frequency is an important parameter.

A seized sample (HN Exodus5) containing 5F-ADB was analysed using inverse-gated decoupling ^{19}F NMR in order to eliminate the nuclear Overhauser effect (NOE), and for providing the added benefit of an enhanced signal to noise (S/N) ratio by collapsing the ^{19}F signals to singlets. The results were compared with proton-coupled ^{19}F NMR; the results from the ^{19}F proton coupled and ^{19}F proton decoupled methods are in good agreement (Fig. S2†). ^1H q-NMR showed $7.1 \pm 0.11 \text{ mg g}^{-1}$ (RSD of 1.57%), ^{19}F proton-coupled q-NMR showed $6.9 \pm 0.02 \text{ mg g}^{-1}$ (RSD of 0.24%), and ^{19}F inverse-gated decoupled q-NMR showed $6.8 \pm 0.08 \text{ mg g}^{-1}$ (RSD of 0.78%).

Two batches of seized "Exodus" brand, 8 seized in 2016 and 7 seized in 2017, were subjected to quantitative analysis using ^{19}F proton coupled/decoupled and ^1H NMR using the IS 2-chloro-4-



Fig. 3 UHPLC chromatograms ($\lambda = 298$ nm) for an "Exodus" sample containing 5F-ADB, RT = 6.8 min, (upper) using 1-methylindazole-3-carboxylic acid as the IS, RT = 5.6 min, showing overlap with a matrix component, (lower) using 5F-AKB48 as the IS, RT = 7.2 min.



fluorotoluene, and also by UHPLC. Confirmation of the quantitation by ^{19}F q-NMR was achieved with UHPLC using the purified 5F-ADB as the reference standard to construct a calibration curve (gradient 1), using $\lambda = 298$ nm wavelength where the indazole absorbs strongly, resulting in $\text{RT} = 6.8$ min. Initially, 1-methylindazole-3-carboxylic acid was used as a UHPLC IS, but this was abandoned due to the overlap of the 1-methylindazole-3-carboxylic acid peak with a plant matrix component at $\text{RT} = 5.6$ min (Fig. 3). 5F-AKB48 ($\text{RT} = 7.2$ min) was chosen instead as an IS in UHPLC analysis due to its similar chromophore to 5F-ADB (indazole), and the presence of an *N*-adamantanyl substituent provided sufficient hydrophobicity to be separated from the peak of 5F-ADB (Fig. 3). The 5F-ADB UHPLC calibration curve using 5F-AKB48 as an IS was in the range of $1.25\text{--}40.00\ \mu\text{g mL}^{-1}$ giving excellent linearity, $R^2 = 0.9999$, and an IS RSD of 4.8% (Fig. 4).

2016 seized “Exodus” sample analyses revealed a consistent dose of 5F-ADB across all 8 samples with an acceptable precision (RSD %) of less than 10% for the analysis of samples in the herbal form (Table 2).²⁷ Furthermore, analysis using ANOVA

two-factor with replication analysis of the four groups (^{19}F coupled, ^{19}F decoupled, ^1H NMR, and UHPLC) revealed no statistically significant differences ($p > 0.05$). However, seven 2017 “Exodus” samples containing 5F-ADB revealed different quantitative results (Table 3). 5 packs of the 7 contained a similar dose of 5F-ADB to the 2016 samples, but samples 5 and 7 contained from 1.5 to more than double the dose of 5F-ADB, with good precision in most of the samples. The presence of such a large quantitative variation in the 2017 samples is alarming, especially as this recently identified SC (5F-ADB) is toxic, being implicated in 10 deaths in Japan,^{28,29} and it is comparable to similar analogues which have approximately 220-fold potency of that of THC, *e.g.* 5F-ADBICA $\text{EC}_{50} = 0.77$ nM compared to THC $\text{EC}_{50} = 172$ nM.¹ The wide deviation and lack of homogeneity of the levels of 5F-ADB both within and between sample packages varied 60 000-fold from $0.8\ \mu\text{g g}^{-1}$ to $49\ \text{mg g}^{-1}$.²⁸ An easy and robust quantitative analysis of fluorinated SCs is clearly important. This technique has the potential to be applied in the rapid analysis of herbal blends sprayed with fluorinated SCs, gaining in importance with the annual increase



Fig. 4 (Upper) stacked UHPLC chromatogram concentrations from 1.25 to $40.0\ \mu\text{g mL}^{-1}$ ($\lambda = 298$ nm) of 5F-ADB ($\text{RT} = 6.8$ min) and 5F-AKB48 IS ($\text{RT} = 7.2$ min); (lower) calibration curve of 5F-ADB against 5F-AKB48 (IS), $R^2 = 0.9999$.

Table 2 Quantification (mg g^{-1}) of SCs in the plant material of the “Exodus” brand seized in 2016 containing 5F-ADB

Sample	NMR $n = 3$				UHPLC $n = 4$			
	^1H	RSD %	^{19}F coupled	RSD %	^{19}F decoupled	RSD %	UHPLC	RSD %
Exodus9	7.39 ± 0.20	2.74	7.34 ± 0.27	3.73	7.12 ± 0.24	3.36	6.96 ± 0.12	1.67
Exodus10	8.04 ± 0.43	5.35	7.87 ± 0.37	4.69	7.87 ± 0.47	5.94	7.92 ± 0.38	4.79
Exodus11	8.24 ± 0.17	2.00	8.01 ± 0.12	1.48	8.05 ± 0.06	0.79	7.87 ± 0.11	1.46
Exodus12	8.04 ± 0.12	1.49	7.89 ± 0.07	0.88	7.93 ± 0.14	1.81	7.97 ± 0.10	1.20
Exodus13	7.78 ± 0.02	0.21	7.71 ± 0.04	0.54	7.72 ± 0.05	0.65	8.19 ± 0.07	0.79
Exodus14	7.65 ± 0.08	1.00	7.61 ± 0.07	0.90	7.66 ± 0.11	1.45	7.91 ± 0.12	1.52
Exodus15	7.57 ± 0.22	2.93	7.52 ± 0.24	3.14	7.50 ± 0.17	2.26	7.54 ± 0.09	1.17
Exodus16	7.43 ± 0.18	2.46	7.45 ± 0.21	2.75	7.48 ± 0.24	3.18	7.94 ± 0.14	1.82



Table 3 Quantification (mg g⁻¹) of SCs in the plant material of the “Exodus” brand seized in 2017 containing 5F-ADB

Sample	NMR <i>n</i> = 3			UHPLC <i>n</i> = 4				
	¹ H	RSD %	¹⁹ F coupled	RSD %	¹⁹ F decoupled	RSD %	UHPLC	RSD %
Exodus1	10.48 ± 0.29	2.78	10.65 ± 0.11	1.08	10.68 ± 0.12	1.11	12.44 ± 0.63	5.03
Exodus2	7.81 ± 0.12	1.51	7.75 ± 0.07	0.92	7.77 ± 0.16	2.09	8.83 ± 0.03	0.34
Exodus3	9.17 ± 0.13	1.41	9.07 ± 0.19	2.13	9.12 ± 0.23	2.55	11.10 ± 1.29	11.60
Exodus4	8.69 ± 0.10	1.17	8.66 ± 0.13	1.49	8.60 ± 0.10	1.12	8.35 ± 0.15	1.80
Exodus5	17.50 ± 0.09	0.53	17.48 ± 0.23	1.31	17.71 ± 0.05	0.26	20.22 ± 0.25	1.23
Exodus6	8.70 ± 0.08	0.93	8.57 ± 0.09	1.01	8.59 ± 0.11	1.33	8.78 ± 0.07	0.83
Exodus7	14.35 ± 0.10	0.69	13.88 ± 0.09	0.66	13.45 ± 0.53	3.92	16.08 ± 0.17	1.06

in the occurrence of such fluorinated third-generation SCs seen in 2016–2019.^{29–32} This analysis is of importance to users/abusers, health professionals and law enforcement to determine how much SC is in the sample. It also clearly demonstrates how there is no quality control of the “Exodus” preparations.

AM-694 quantified in seized herbal blends

[1-(5-Fluoropentyl)-1*H*-indol-3-yl](2-iodophenyl)-methanone (AM-694) was isolated from seized herbal blends (3.0 g) branded

as “Loco elite”. Identification was achieved through 2D NMR spectroscopy and its LC-MS/MS fragmentation pattern. Results were confirmed by comparison with the published literature of the first analytical characterization of illicit AM-694 from seizures.⁶ Candidate signals for integration are 3'', 4'', 5'', and 6'' of the 2-iodophenyl substituent, 2' and 7' of the indole core, and 1''' and 5''' of the fluoropentyl chain. The impact of relaxation delay in ¹⁹F NMR was investigated, and it was found that using only a short relaxation delay (<15 s) significantly affected the quantitative results. 15 s and 30 s relaxation delays were sufficient to achieve reproducible quantitative results. Moreover,



Fig. 5 (Upper) expansion of the ¹H NMR aromatic region of AM-694 in CD₃OD showing signals used for quantification where the integration of the 2-chloro-4-fluorotoluene IS H5 signal (td) is normalized (1.00 H); (lower) ¹⁹F NMR signals of AM-694 at –220 ppm and the same IS ¹⁹F signal at –117 ppm also normalized (1.00 F).





Fig. 6 (Upper) UHPLC chromatogram ($\lambda = 254$ nm) of AM-694 (RT = 6.9 min) and JWH-018 (RT = 7.3 min); (lower) calibration curve of AM-694 against JWH-018 (IS), $R^2 = 0.997$.

Table 4 Quantitative analysis of AM-694 in "Loco elite" herbal blends by ^1H and ^{19}F NMR, using maleic acid (MA) or 2-chloro-4-fluorotoluene as the IS, and UHPLC (against JWH-018)

Analysis method (IS)	^1H (MA)	^1H (2-chloro-4-fluorotoluene)	^{19}F (2-chloro-4-fluorotoluene)	UHPLC (JWH-018)
Sample 1 (mg g^{-1}) ^a	57.0 ± 2.9	n.d.	n.d.	n.d.
RSD (%)	5.2	—	—	—
Sample 2 (mg g^{-1}) ^a	37.5 ± 1.1	36.7 ± 2.0	35.4 ± 0.6	38.4 ± 2.6
RSD (%)	3.0	5.4	1.7	6.6

^a mg of AM-694 per gram of herbal sample.

such relaxation delays still allowed fast overall sample run-times of 8 and 10 min, respectively. ^1H q-NMR and ^{19}F q-NMR showed consistent results when using 2-chloro-4-fluorotoluene as the IS (Fig. 5). Furthermore, cross-method validation was demonstrated using UHPLC with reference standard AM-694, RT = 6.9 min, and JWH-018 (IS), RT = 7.3 min, constructing a seven-point calibration curve between 1.25 and 80.0 μg with $R^2 = 0.997$ and IS RSD = 4.4% (Fig. 6).

Two samples were quantified, with significant differences ($p < 0.05$) in their AM-694 content. Sample 1 analysis using (only) ^1H NMR spectroscopy, with maleic acid as the IS, showed 57.0 ± 2.9 mg g^{-1} of plant material, compared to the value for Sample 2 of 37.5 ± 1.1 mg . The latter ^1H NMR quantification of Sample 2 was shown to be consistent when analysed by ^1H NMR spectroscopy against both maleic acid and 2-chloro-4-fluorotoluene

as the IS, and by ^{19}F q-NMR, and also in agreement with UHPLC results, showing no significant differences between these methods using Anova two-factor analysis ($p > 0.05$) (Table 4).

In the ^1H NMR when using 2-chloro-4-fluorotoluene as the IS, its H6 signal overlapped with 5' of the indole and indazole SC. Nevertheless, other AM-694 signals such as 4'', 6'', and 7' were resolved and used as candidate quantitative signals in CD_3OD . 5-Fluoropentyl signals 1''' and 5''' were resolved when CDCl_3 or CD_3CN was used as the NMR solvent, providing further options for q-NMR analysis.

Conclusions

In this study, ^{19}F -NMR spectroscopy has been applied for the first time to seized herbal blends containing fluorinated 3rd



generation SCs to provide a fast (~8 min), accurate and robust quantitative analytical method with no background interference from the plant-material matrix. This analytical technique requires almost no method development (beyond the NMR acquisition parameters) compared to chromatographic methods. There is no need to resort to any lengthy chromatographic analysis. 2-Chloro-4-fluorotoluene was used as an IS in ^{19}F q-NMR, resulting in a method with close agreement with ^1H q-NMR results using two different ISs, and cross-method validation was performed using UHPLC.

Acquisition parameters such as the centre point of the spectral window and the relaxation delay have to be chosen carefully for accurate and precise outcomes. An inverse-gated decoupling NMR experiment was employed to improve the S/N ratio and to remove any NOE enhancement. That such analytical data are important is underlined by the analysis of packets of the “Exodus” brand containing 5F-ADB which revealed quantitative differences between 2016 and 2017 seizures in the dose of 5F-ADB, with some packets having double the dose compared to others.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

We acknowledge the Drug Expert Action Team (DEAT), Avon and Somerset Constabulary, for the provision of seized samples, and the Government of Kuwait (a fully funded studentship to HAN).

References

- 1 S. D. Banister, M. Moir, J. Stuart, R. C. Kevin, K. E. Wood, M. Longworth, S. M. Wilkinson, C. Beinat, A. S. Buchanan, M. Glass, M. Connor, I. S. McGregor and M. Kassiou, Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADBPINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA, *ACS Chem. Neurosci.*, 2015, **6**, 1546–1559.
- 2 S. Tai and W. E. Fantegrossi, Synthetic cannabinoids: Pharmacology, behavioral effects, and abuse potential, *Current Addiction Reports*, 2014, **1**, 129–136.
- 3 V. Auwärter, S. Dresen, W. Weinmann, M. Muller, M. Putz and N. Ferreiros, ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?, *J. Mass Spectrom.*, 2009, **44**, 832–837, DOI: 10.1002/jms.1558.
- 4 J. W. Huffman, D. Dai, B. R. Martin and D. R. Compton, Design, synthesis, and pharmacology of cannabimimetic indoles, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 563–566.
- 5 S. D. Banister, J. Stuart, R. C. Kevin, A. Edington, M. Longworth, S. M. Wilkinson, C. Beinat, A. S. Buchanan, D. E. Hibbs, M. Glass, M. Connor, I. S. McGregor and M. Kassiou, Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135, *ACS Chem. Neurosci.*, 2015, **6**, 1445–1458.
- 6 J. I. Nakajima, M. Takahashi, T. Seto, C. Kanai, J. Suzuki, M. Yoshida and T. Hamano, Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the internet, *Forensic Toxicol.*, 2011, **29**, 95–110.
- 7 N. Uchiyama, Y. Shimokawa, R. Kikura-Hanajiri, Y. Demizu, Y. Goda and T. Hakamatsuka, A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N-OH-EDMA, and a cathinone derivative dimethoxy- α -PHP, newly identified in illegal products, *Forensic Toxicol.*, 2015, **33**, 244–259, DOI: 10.1007/s11419-015-0268-7.
- 8 H. Chung, H. Choi, S. Heo, K. Eunmi and J. Lee, Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013, *Forensic Toxicol.*, 2014, **32**, 82–88.
- 9 A. Makriyannis and H. Deng, University of Connecticut. Cannabimimetic indole derivatives, Patent US6900236B1, 2005, <https://patentimages.storage.googleapis.com/9d/ec/b4/ea8af239e287da/US6900236.pdf>, accessed 17/04/19.
- 10 S. M. Wilkinson, S. D. Banister and M. Kassiou, Bioisosteric fluorine in the clandestine design of synthetic cannabinoids, *Aust. J. Chem.*, 2015, **68**, 4–8.
- 11 A. Zivkovic, J. J. Bandolik, A. J. Skerhut, C. Coesfeld, M. Prascevic, L. Zivkovic and H. Stark, Quantitative analysis of multicomponent mixtures of over-the counter pain killer drugs by low-field NMR spectroscopy, *J. Chem. Educ.*, 2017, **94**, 121–125, DOI: 10.1021/acs.jchemed.6b00105.
- 12 G. Maniara, K. Rajamoorthi, S. Rajan and G. W. Stockton, Method performance and validation for quantitative analysis by ^1H and ^{31}P NMR spectroscopy. Applications to analytical standards and agricultural chemicals, *Anal. Chem.*, 1998, **70**, 4921–4928.
- 13 U. Holzgrabe, Quantitative NMR spectroscopy in pharmaceutical applications, *Prog. Nucl. Magn. Reson. Spectrosc.*, 2010, **57**, 229–240.
- 14 P. A. Hays, Proton nuclear magnetic resonance spectroscopy (NMR) methods for determining the purity of reference drug standards and illicit forensic drug seizures, *J. Forensic Sci.*, 2005, **50**, 1342–1360.
- 15 F. Malz and H. Jancke, Validation of quantitative NMR, *J. Pharm. Biomed. Anal.*, 2005, **38**, 813–823.
- 16 J. P. Smith, O. B. Sutcliffe and C. E. Banks, An overview of recent developments in the analytical detection of New Psychoactive Substances (NPSs), *Analyst*, 2015, **140**, 4932–4948.
- 17 A. Frinculescu, C. L. Lyall, J. Ramsey and B. Miserez, Variation in commercial smoking mixtures containing third-generation synthetic cannabinoids, *Drug Test. Anal.*, 2017, **9**, 327–333.



- 18 F. Fowler, B. Voyer, M. Marino, J. Finzel, M. Veltri, N. M. Wachter and L. Huang, Rapid screening and quantification of synthetic cannabinoids in herbal products with NMR spectroscopic methods, *Anal. Methods*, 2015, **7**, 7907–7916.
- 19 S. J. Dunne and J. P. Rosengren-Holmberg, Quantification of synthetic cannabinoids in herbal smoking blends using NMR, *Drug Test. Anal.*, 2017, **9**, 734–743.
- 20 G. F. Pauli, B. U. Jaki and D. C. Lankin, Quantitative ^1H NMR: development and potential of a method for natural products analysis, *J. Nat. Prod.*, 2005, **68**, 133–149.
- 21 R. Martino, V. Gilard, F. Desmoulin and M. Malet-Martino, Fluorine-19 or phosphorus-31 NMR spectroscopy: A suitable analytical technique for quantitative *in vitro* metabolic studies of fluorinated or phosphorylated drugs, *J. Pharm. Biomed. Anal.*, 2005, **38**, 871–891.
- 22 S. J. Barry, T. N. Pham, P. J. Borman, A. J. Edwards and S. A. Watson, A risk-based statistical investigation of the quantification of polymorphic purity of a pharmaceutical candidate by solid-state ^{19}F NMR, *Anal. Chim. Acta*, 2012, **712**, 30–36, DOI: 10.1016/j.aca.2011.10.064.
- 23 A. J. Adams, S. D. Banister, L. Irizarry, J. Trecki, M. Schwartz and R. Gerona, “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York, *N. Engl. J. Med.*, 2017, **376**, 235–242, DOI: 10.1056/nejmoa1610300.
- 24 B. K. Logan, L. E. Reinhold, A. Xu and F. X. Diamond, Identification of synthetic cannabinoids in herbal incense blends in the United States, *J. Forensic Sci.*, 2012, **57**, 1168–1180.
- 25 V. Shevyrin, V. Melkozerov, A. Nevero, O. Eltsov, Y. Shafran, Y. Morzherin and A. T. Lebedev, Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a *N*-1-methoxycarbonylalkyl group, *Anal. Bioanal. Chem.*, 2015, **407**, 6301–6315, DOI: 10.1007/s00216-015-8612-7.
- 26 S. Akamatsu and M. Yoshida, Fragmentation of synthetic cannabinoids with an isopropyl group or a *tert*-butyl group ionized by electron impact and electrospray, *J. Mass Spectrom.*, 2016, **51**, 28–32.
- 27 European Network of Forensic Science Institutes - Drugs Working Group, *Guidelines on sampling of illicit drugs for quantitative analysis*, 2014, http://enfsi.eu/wp-content/uploads/2016/09/guidelines_quant_sampling_dwg_printing_vf4.pdf accessed 17/04/19.
- 28 K. Hasegawa, A. Wurita, K. Minakata, K. Gonmori, I. Yamagishi, H. Nozawa, K. Watanabe and O. Suzuki, Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products, *Forensic Toxicol.*, 2015, **33**, 112–121, DOI: 10.1007/s11419-014-0259-0.
- 29 S. D. Banister, M. Longworth, R. Kevin, S. Sachdev, M. Santiago, J. Stuart, J. B. C. Mack, M. Glass, I. S. McGregor, M. Connor and M. Kassiou, Pharmacology of valinate and *tert*-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues, *ACS Chem. Neurosci.*, 2016, **7**, 1241–1254, DOI: 10.1021/acschemneuro.6b00137.
- 30 M. D. P. Risseuw, P. Blanckaert, V. Coopman, S. Van Quekelberghe, S. Van Calenbergh and J. Cordonnier, Identification of a new *tert*-leucinate class synthetic cannabinoid in powder and “spice-like” herbal incenses: methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (5F-MDMB-PICA), *Forensic Sci. Int.*, 2017, **273**, 45–52, DOI: 10.1016/j.forsciint.2017.01.023.
- 31 L. Mogler, F. Franz, D. Rentsch, V. Angerer, G. Weinfurter, M. Longworth, S. D. Banister, M. Kassiou, B. Moosmann and V. Auwärter, Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in ‘legal high’ products and human urine samples, *Drug Test. Anal.*, 2018, **10**, 196–205, DOI: 10.1002/dta.2201.
- 32 S. D. Banister, A. Adams, R. C. Kevin, C. Macdonald, M. Glass, R. Boyd, M. Connor, I. S. McGregor, C. M. Havel, S. J. Bright, M. V. Vilamala, C. G. Lladanosa, M. J. Barratt and R. R. Gerona, Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA, *Drug Test. Anal.*, 2019, **11**, 279–291, DOI: 10.1002/dta.2491.

